In vitro and in vivo delivery of atorvastatin: A comparative study of anti-inflammatory activity of atorvastatin loaded copolymeric micelles
Source abstract
Abstract
Statins have been shown to exert ‘pleiotropic effects’ independent of their cholesterol lowering actions that include anti-inflammatory properties. In this study we synthesized mono methoxy poly (ethylene glycol)–poly (ε-caprolactone) (mPEG-PCL) di block copolymers. The structure of the copolymers was characterized by H nuclear magnetic resonance, Fourier-transform infrared spectroscopy, differential scanning calorimetry and gel permeation chromatography techniques. In this method, atorvastatin was encapsulated within micelles through a single-step nano-precipitation method, leading to the formation of atorvastatin-loaded mPEG-PCL (atorvastatin/mPEG-PCL) micelles. The resulting micelles were characterized further by various techniques such as dynamic light scattering and atomic force microscopy. In this study the anti-inflammatory activity of atorvastatin and atorvastatin/mPEG-PCL micelles on acute models of inflammation are analyzed, to compare the effect of indometacin in rats. Carrageenan induces rat paw edema; six animals of each group (10 groups) received indometacin, atorvastatin, and atorvastatin/mPEG-PCL micelles orally 1, 6, 12 and 24 h before carrageenan injection in paw. The paw edema thickness measured at 1, 2, 3 and 4 h after injection and percentage inhibition of edema in various groups were calculated. The results showed that the zeta potential of micelles was about −16.6 mV and the average size was 81.7 nm. Atorvastatin was encapsulated into mPEG-PCL micelles with loading capacity of 14.60 ± 0.96% and encapsulation efficiency of 62.50 ± 0.84%. Atorvastatin and atorvastatin/mPEG-PCL micelles showed significant anti-inflammatory activity in the present study. The anti-inflammatory activity of atorvastatin and atorvastatin/mPEG-PCL micelles was significant in comparison with indometacin. Atorvastatin/mPEG-PCL micelles showed more anti-inflammatory activity than atorvastatin. This study revealed the anti-inflammatory activity of atorvastatin and atorvastatin/mPEG-PCL micelles and suggested the statins have a potential inflammatory activity along with its lipid lowering properties. Contrary to anti-inflammatory effects, the pro-inflammatory responses are independent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition and can be mediated directly by atorvastatin.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Lipoproteins and Cardiovascular Health · Computational Drug Discovery Methods · Cancer, Lipids, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Zanjan Applied Pharmacology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
Zanjan Pharmaceutical Nanotechnology Research Center, Zanjan University of Medical Sciences, Zanjan, Iran
References (30)
Show source-provided references
1. 10.1016/S1568-9972(03)00049-110.1016/S1568-9972(03)00049-1 ↗
2. 10.1291/hypres.23.18710.1291/hypres.23.187 ↗
3. Weitz SG. · Sciences · 2002 · 23 · 482
4. 10.1038/nature0115810.1038/nature01158 ↗
5. 10.1006/phrs.2001.092210.1006/phrs.2001.0922 ↗
6. 10.1001/jama.279.20.161510.1001/jama.279.20.1615 ↗
7. 10.1161/01.CIR.98.9.83910.1161/01.CIR.98.9.839 ↗
8. 10.1016/j.tcm.2005.07.00210.1016/j.tcm.2005.07.002 ↗
9. 10.1002/mnfr.20050008110.1002/mnfr.200500081 ↗
10. 10.1161/01.STR.0000226901.34927.1010.1161/01.STR.0000226901.34927.10 ↗
11. 10.1080/03639045.2017.135592210.1080/03639045.2017.1355922 ↗
12. 10.4049/jimmunol.176.9.528410.4049/jimmunol.176.9.5284 ↗
13. 10.1080/21691401.2017.134788010.1080/21691401.2017.1347880 ↗
14. Lin SY · Pharm Acta Helv · 1985 · 60 · n339
15. 10.1055/s-0042-10986510.1055/s-0042-109865 ↗
16. 10.1016/0168-3659(94)90237-210.1016/0168-3659(94)90237-2 ↗
17. Danafar H. · Jundishapur J Nat Pharm Prod · 2017 · 12 · e34179
18. 10.1038/bjc.1996.58710.1038/bjc.1996.587 ↗
19. 10.1007/s11164-017-3084-310.1007/s11164-017-3084-3 ↗
20. Nosrati H, Salehiabar M, Manjili HK, et al. Preparation of magnetic albumin nanoparticles via a simple and one-pot desolvation and co-precipitation method for medical and pharmaceutical applications. Int J Biol Macromol . Epub ahead of print 2017. DOI: 10.1016/j.ijbiomac.2017.10.180.10.1016/j.ijbiomac.2017.10.180 ↗
21. Salehiabar M, Nosrati H, Davaran S, et al. Facile synthesis and characterization of l-aspartic acid coated iron oxide magnetic nanoparticles (IONPs) for biomedical applications. Drug Res 2017. DOI: 10.1055/s-0043-120197.10.1055/s-0043-120197 ↗
22. 10.1177/088532821769806310.1177/0885328217698063 ↗
23. Danafar H · Artif Cells NanomedBiotechnol · 2017 · 1
24. 10.1080/21691401.2017.128250110.1080/21691401.2017.1282501 ↗
25. 10.1055/s-0042-11093110.1055/s-0042-110931 ↗
26. 10.1055/s-0043-10605110.1055/s-0043-106051 ↗
27. 10.1007/s10337-013-2548-x10.1007/s10337-013-2548-x ↗
28. 10.15171/PS.2015.3210.15171/PS.2015.32 ↗
29. 10.1016/0009-8981(60)90004-810.1016/0009-8981(60)90004-8 ↗
30. 10.1093/clinchem/28.10.207710.1093/clinchem/28.10.2077 ↗